Adding immunotherapy after initial treatment improves survival in metastatic NSCLC patients

Treating metastatic non-small cell lung cancer patients with the immunotherapy drug pembrolizumab after they’ve completed locally ablative therapy – meaning all known sites of their cancer were either treated with surgery, radiation, or other definitive treatments – almost tripled the median progression-free survival compared to the historical average.

From http://besthealthnews.com/2019/07/adding-immunotherapy-after-initial-treatment-improves-survival-in-metastatic-nsclc-patients/?utm_source=rss&utm_medium=rss&utm_campaign=adding-immunotherapy-after-initial-treatment-improves-survival-in-metastatic-nsclc-patients

from
https://healthnews010.wordpress.com/2019/07/12/adding-immunotherapy-after-initial-treatment-improves-survival-in-metastatic-nsclc-patients/

From https://jamesjohnson10.blogspot.com/2019/07/adding-immunotherapy-after-initial.html

from
https://jamesjohnson10.wordpress.com/2019/07/12/adding-immunotherapy-after-initial-treatment-improves-survival-in-metastatic-nsclc-patients/

from https://judywright2.blogspot.com/2019/07/adding-immunotherapy-after-initial.html

from
https://judywright2.tumblr.com/post/186233282317